PL349070A1 - Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors - Google Patents

Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors

Info

Publication number
PL349070A1
PL349070A1 PL00349070A PL34907000A PL349070A1 PL 349070 A1 PL349070 A1 PL 349070A1 PL 00349070 A PL00349070 A PL 00349070A PL 34907000 A PL34907000 A PL 34907000A PL 349070 A1 PL349070 A1 PL 349070A1
Authority
PL
Poland
Prior art keywords
acetylenic
sulfonamido
ortho
bicyclic heteroaryl
phosphinic acid
Prior art date
Application number
PL00349070A
Other languages
English (en)
Inventor
Jeremy Ian Levin
James Ming Chen
Xue-Mei Du
Jay Donald Albright
Arie Zask
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of PL349070A1 publication Critical patent/PL349070A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/78—Halides of sulfonic acids
    • C07C309/86—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/87—Halides of sulfonic acids having halosulfonyl groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
PL00349070A 1999-01-27 2000-01-27 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors PL349070A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23908499A 1999-01-27 1999-01-27

Publications (1)

Publication Number Publication Date
PL349070A1 true PL349070A1 (en) 2002-07-01

Family

ID=22900535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00349070A PL349070A1 (en) 1999-01-27 2000-01-27 Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors

Country Status (22)

Country Link
EP (2) EP1157024B1 (de)
JP (1) JP2002535404A (de)
KR (1) KR20010101690A (de)
CN (1) CN1207294C (de)
AR (1) AR022424A1 (de)
AT (1) ATE227288T1 (de)
AU (1) AU2741800A (de)
BR (1) BR0007760A (de)
CA (1) CA2355735A1 (de)
CZ (1) CZ20012721A3 (de)
DE (1) DE60000724T2 (de)
DK (1) DK1157024T3 (de)
EA (1) EA200100814A1 (de)
ES (1) ES2186628T3 (de)
HK (1) HK1038562B (de)
HU (1) HUP0105307A3 (de)
IL (1) IL144291A0 (de)
NO (1) NO20013673L (de)
PL (1) PL349070A1 (de)
PT (1) PT1157024E (de)
WO (1) WO2000044749A1 (de)
ZA (1) ZA200104324B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
EP1449538A1 (de) 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modulation der EGF Rezeptor Signalübertragung durch Hemmung von TACE oder Amphiregulin
WO2004110454A1 (ja) * 2003-06-13 2004-12-23 Ishihara Sangyo Kaisha, Ltd. アデノシンＡ2ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
EP2170884A2 (de) * 2007-06-25 2010-04-07 Boehringer Ingelheim International GmbH Chemische verbindungen
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934300B1 (de) * 1996-10-16 2002-12-18 American Cyanamid Company Herstellung und verwendung von ortho-sulfonamido-heteroarylhydroxamsäuren als matrix-metalloproteinase und tace inhibitoren
AU743901B2 (en) * 1996-10-16 2002-02-07 Wyeth Holdings Corporation Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors

Also Published As

Publication number Publication date
ZA200104324B (en) 2002-08-26
AR022424A1 (es) 2002-09-04
EP1279674A2 (de) 2003-01-29
BR0007760A (pt) 2001-11-13
HUP0105307A3 (en) 2002-10-28
CA2355735A1 (en) 2000-08-03
EP1157024B1 (de) 2002-11-06
KR20010101690A (ko) 2001-11-14
WO2000044749A1 (en) 2000-08-03
HK1038562B (en) 2003-02-21
DE60000724T2 (de) 2003-08-21
CN1337962A (zh) 2002-02-27
CN1207294C (zh) 2005-06-22
HK1038562A1 (en) 2002-03-22
DK1157024T3 (da) 2003-03-03
AU2741800A (en) 2000-08-18
EP1279674A3 (de) 2003-10-01
IL144291A0 (en) 2002-05-23
EA200100814A1 (ru) 2001-12-24
NO20013673L (no) 2001-09-21
JP2002535404A (ja) 2002-10-22
CZ20012721A3 (cs) 2002-03-13
PT1157024E (pt) 2003-02-28
HUP0105307A2 (hu) 2002-05-29
DE60000724D1 (en) 2002-12-12
ES2186628T3 (es) 2003-05-16
NO20013673D0 (no) 2001-07-26
EP1157024A1 (de) 2001-11-28
ATE227288T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
AU4692399A (en) Cyclic hydroxamic acids as metalloproteinase inhibitors
IL144783A0 (en) Sulfamato hydroxamic acid metalloprotease inhibitor
PL349900A1 (en) Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
EP0810858A4 (de) Boronsäure und deren ester als thrombininhibitoren
ZA979235B (en) The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
ZA979233B (en) The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL129148A0 (en) The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
EP1389107A4 (de) Bisarylimidazolyl-fettsäureamid-hydrolase-hemmer
AU4153197A (en) Phosphinic acid amides as matrix metalloprotease inhibitors
AU2001280633A1 (en) Phosphate esters of bis-amino acid sulfonamides containing substituted benzyl amines
EP1487776A4 (de) Säure- und esterverbindungen und verfahren zu deren anwendung
HUP0003880A3 (en) Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same
IL144348A0 (en) Alkynyl containing hydroxamic acid compounds as tace inhibitors
PL349070A1 (en) Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
IL151250A0 (en) Difluorobutyric acid metalloprotease inhibitors
PL356092A1 (en) Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
IL144321A0 (en) ACETYLENIC β-SULFONAMIDO AND PHOSPHINIC ACID AMIDE HYDROXAMIC ACID AS TACE INHIBITORS
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
SI1157024T1 (en) Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as tace inhibitors
IL144346A0 (en) Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
HK1038012A (en) Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
HUP0100056A3 (en) Carboxyl acid substituted heterocycles as metalloproteinase inhibitors, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
HK1037612A (en) Acetylenic (beta)-sulfonamido and phosphinic acid amide hydroxamic acid tace inhibitors
HK1038226A (en) Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
PL332532A1 (en) Method of obatining 4-amino-5-hexenic acid

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)